Neuroscience | Novartis

Media Release
Aug 25, 2023
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Media Release
Jul 17, 2023
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
Media Release
Jun 30, 2023
Novartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
Interior Page
Neuroscience
Media Release
Apr 20, 2023
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Media Release
Jul 25, 2022
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Media Release
Sep 21, 2022
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Story
Oct 13, 2022
In neuroscience, “an inflection point in knowledge and technology”
Media Release
Jun 27, 2022
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Media Release
Jun 17, 2022
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Media Release
Apr 05, 2022
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Media Release
Mar 02, 2022
Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis